Processa Acquisition Lands Immunology Drug That Could Rival a New Novartis Product
With the merger, Processa’s new lead asset is a Vidya Therapeutics immunology drug that provides pipeline-in-a-product potential addressing a goal ...
With the merger, Processa’s new lead asset is a Vidya Therapeutics immunology drug that provides pipeline-in-a-product potential addressing a goal ...
One ingredient, seven supply codecs. Zembrin®, the standardized kanna extract from PLT Well being Options, is now exhibiting up in ...
Kardigan was capable of upsize its IPO, elevating more money for 3 drug candidates in mid-stage scientific improvement for cardiovascular ...
There are not any FDA-approved therapies for GPC3, a protein extremely expressed by liver cancers. Oricell Therapeutics claims its cell ...
Zarminali Pediatrics, an outpatient pediatric supplier, has raised $110 million in Collection A funding to increase to extra sufferers, the ...
C4 Vitality Cereal Killer simply landed at 12,000+ 7-Eleven and Speedway shops nationwide. What began as a restricted Halloween drop ...
Women are twice as likely as men to experience depression and anxiety. And about one in three women will battle ...
A Bayer drug designed to target tumors driven by a rare genetic mutation now has accelerated FDA approval, providing another ...
Nourish, a nutrition counseling company, announced Wednesday that it raised $70 million in Series B funding for its network of ...
A clinical trial is typically the first look at how an experimental drug works in humans. Character Biosciences is entering ...
Copyright © 2025 Your Health 24 7.
Your Health 24 7 is not responsible for the content of external sites.
Copyright © 2025 Your Health 24 7.
Your Health 24 7 is not responsible for the content of external sites.